Dean M Wingerchuk

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

D. Wingerchuk, Dean M Wingerchuk, Jonathan L Carter, 2014, Mayo Clinic proceedings.

The spectrum of neuromyelitis optica

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2007, The Lancet Neurology.

Multiple Sclerosis: Current Pathophysiological Concepts

C. Lucchinetti, J. Noseworthy, D. Wingerchuk, 2001, Laboratory Investigation.

Neuromyelitis optica and non organ-specific autoimmunity.

Patrick Vermersch, P. Vermersch, B. Weinshenker, 2008, Archives of neurology.

Determination of Hemispheric Language Dominance in the Surgical Epilepsy Patient: Diagnostic Properties of Functional Magnetic Resonance Imaging

Bart M Demaerschalk, R. Zimmerman, B. Demaerschalk, 2012, The neurologist.

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

Ichiro Nakashima, K. Fujihara, B. Weinshenker, 2004, The Lancet.

Neuromyelitis optica

B. Weinshenker, D. Wingerchuk, Dean M Wingerchuk, 2003, Neurology.

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Gary R Cutter, Friedemann Paul, Fred D Lublin, 2019, The Lancet.